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Functionally distinct subsets of thymus-derived (T) cells differ with regard to 
their Ly surface phenotype (1-3). Peritoneal T cells of C57BL/6  (B6) mice which 
are cytotoxic for BALB/c target cells are Ly-l-, Ly-2/3 +, whereas B6 spleen cells 
which perform a "helper  function" in the production of antibody to sheep red 
blood cells are Ly-1 ÷, Ly-2/3-. We report here that cytotoxic T cells for syngeneic 
tumor cells belong to a different T-cell subset than cytotoxic cells for allogeneic 
target cells. 
Materials  and Methods 
Immunization  and  Microcytotoxicity  Assay.  B6  sarcoma  Meth  4,  induced by  subcutaneous 
injection of methylcholanthrene, was in its 5th to 15th transplant generation in syngeneic mice 
during these studies. B6 female donors received four weekly intraperitoneal injections of 5  ×  106 
irradiated (10,000 rads) Meth 4 cells or 5  ×  l0  s B6 or BALB/c spleen cells. Peritoneal cells were 
harvested 3 days after the last immunization and were incubated with [3H]proline-labeled mono- 
layer target cells for 24 or 36 h.  (In our experience, lymphocyte cytotoxicity in syngeneic tumor 
systems requires a longer incubation period for maximal target cell destruction than in allogeneic 
reactions [12-20 h incubation].) Detached target cells and effector cells were removed by washing 
and the radioactivity (counts per minute) of the remaining cells was measured.  (For details of 
microcytotoxicity assay, see reference 4.) 
Pretreatment  of  Cytotoxic  Peritoneal  Lymphocytes  with  Antiserum  and  Complement  (1, 
2).  Peritoneal cells from groups of five B6 mice immunized with either Meth 4 cells (immune) or 
syngeneic  spleen  cells  (nonimmune)  were  pooled.  Peritoneal  lymphocytes  were  obtained  by 
removing glass-adherent cells,  as described previously (1, 4).  For pretreatment with antiserum 
and complement (C),  equal volumes of (a) lymphocytes (5  x  108/ml),  (b) appropriately diluted 
antiserum (titers were determined by standard C-dependent cytotoxicity assays and the dilutions 
chosen for tests covered the range of maximal cytotoxicity for peritoneal lymphocytes), and (c) C 
(selected rabbit serum [1/15] for mouse antisera, or guinea pig serum [1/3] for rabbit antisera) was 
mixed and incubated for 45 min at 37°C. The medium was Eagle's balanced salt solution with 2.5% 
fetal  bovine  serum,  100  U/ml  penicillin,  and  100  ~g/ml  streptomycin.  For  control  purposes, 
antisera against reciprocal  Ly or Thy-1  alleles,  or normal rabbit serum  (in the case of rabbit 
antisera) were used.  Specificity was further confirmed by absorption tests with thymocytes from 
mice of congenic Ly strains (5). After pretreatment with antiserum and C, washed lymphocytes (2 
×  105 or 4 ×  105 viable lymphocytes per well) were incubated with [~H]proline-labeled target cells 
(1 × 103 per well) for 36 h at 37°C in 5% CO2 in air. 'Tercent cell-mediated cytotoxicity (CMC)" was 
calculated according to the formula [1 -  (a)/(b)]  ×  100, where (a) and (b) represent counts per 
minute of remaining target cells after incubation with immune lymphocytes (a) or nonimmune 
* Supported by Grant CRI-287 of the Cancer Research Institute, Inc. and grants CA-08748 and 
CA-17404 of the National Cancer Institute. 
$ Present address: Virginia Mason Research Center, Seattle, Wash. 
1116  THE  JOURNAL  OF  EXPERIMENTAL  MEDICINE"  VOLUME  144, 1976 SHIKU  ET  AL.  BRIEF  DEFINITIVE  REPORT  1117 
=  ~  15oo 
Em 
~a 
900 
=  300 
Target cell B6 Meth 4  Target cell BALB/c 
Meth 113  3ooop  __  4000  / 
-~  1800  ~-  2400  I 
600 L~  ~  800 
50  100  200  50  100  200  50 
Number  of  effector  cells  per  well  (x  10  "3) 
Target  cell  B6  lung  fil>roblast 
I_  I 
10o  20o 
FIa.  1.  B6 donors received 4 weekly intraperitoneal injections of 5  ×  10  s (a) B6 sarcoma 
Meth 4 cells (10,000 rads),  (b) B6 spleen cells, or (c) BALB/c spleen cells. Peritoneal cells 
harvested 3 days after the last injections were incubated with  [3H]proline-labeled mono- 
layer target cells.  (---),  no peritoneal cells; ($---O), peritoneal cells from B6 mice injected 
with irradiated B6 sarcoma Meth 4;  (A--A), peritoneal cells from B6 mice injected with 
BALB/c spleen cells;  and  (D--D),  peritoneal cells from B6 mice injected with B6 spleen 
cells. 
lymphocytes  (b).  Percent reduction of CMC resulting from pretreatment of peritoneal lympho- 
cytes was calculated as [1 -  (A)/(B)] ×  100, where (A) is percent CMC (see above) oflymphocytes 
pretreated with test antisera and C,  and  (B)  is percent CMC  of lymphocytes pretreated with 
control serum and C. 
Results and Discussion 
Fig.  1 shows cytotoxic assays with peritoneal cells from B6 mice immunized 
with the syngeneic methylcholanthrene-induced sarcoma, Meth 4. These cells 
destroyed Meth 4 cells, but not B6 lung fibroblasts or BALB/c sarcoma Meth 113 
cells (Fig. 1). Peritoneal cells from B6 mice immunized with BALB/c spleen cells 
were cytotoxic for BALB/c target cells, but not for Meth 4 cells. The definition of 
surface antigens of chemically induced tumors is not sufficiently advanced to say 
which antigens are involved in this syngeneic cell-mediated killing.  Current 
evidence points to surface antigens related to murine leukemia virus (MuLV), 
rather than the individually distinct antigens demonstrable by transplantation 
techniques, since Meth 4 is MuLV + and peritoneal lymphocytes from B6 mice 
immunized with Meth 4 cells lyse three other MuLV  + B6 sarcomas. 
To analyze the surface phenotype of syngeneic cytotoxic cells, subpopulations 
of peritoneal lymphocytes were prepared by eliminating cells marked by one or 
another T- or B-cell surface antigen through the use of cytotoxic antiserum and 
C (1, 2, 5). Pretreatment with antisera against Thy-1, mouse-specific T-lympho- 
cyte antigen (MSLA) or Ig showed that the cytotoxic cells for syngeneic Meth 4 
cells, as in our earlier experiments with allogeneic target cells (1, 4, 6), have a 
Thy-1  +, MSLA  +, Ig- phenotype (Table I). Pretreatment of immune B6 lympho- 
cytes (phenotype Ly-1.2,2.2,3.2) with anti-Ly-l.2, anti-Ly-2.2, or anti-Ly-3.2 sera 
reduced their cytotoxicity for Meth 4 cells (Table II). Additional confirmation of 
the specificity of  these reactions was obtained in the experiment shown in Fig. 2. 
The reduction of B6 T-cell cytotoxicity for Meth 4 cells by treatment with anti- 
Ly-l.2 serum was prevented by absorption with B6 thymocytes (phenotype Ly- 
1.2), but not by absorption with thymocytes  from congenic B6/Ly-1.1 mice (1). 1118  SHIKU  ET  AL.  BRIEF  DEFINITIVE  REPORT 
TABLE  I 
Effect  of Pretreatment of Syngeneic Cytotoxic Cells with Anti-Thy-1, 
Anti-MSLA, and Anti-Ig Sera 
Pretreatment of peri- 
toneal lymphocytes* 
Exp.  1  Exp.  2 
CMC  Reduction of CMC  CMC  Reduction  of  CMC 
%  %  %  % 
Test for Thy-t 
Diluent only  72  70 
Anti-Thy-l. I  76  Standard  73  Standard 
Anti.Thy-l.2  4  95  11  85 
Test for MSLA and Ig 
Diluent only  66  66 
NRS$  54  Standard  56  Standard 
Anti-MSLA  4  93  8  80 
Anti-Fab  80  - 48§  NI~[ 
Anti-K  NI~I  76  -36§ 
* With C; this applies to all other experiments. 
$ Normal rabbit serum. 
§ A  negative entry signifies an increase in CMC,  attributable most probably to an increase  in the 
relative proportion of T  cells present  (since  the  number  of viable cells added  to each  well,  after 
pretreatment,  was adjusted to equal the number of viable control ]ympbocytes  added). 
I[  ND,  not done. 
TABLE II 
Effect of Pretreatment of Syngeneic Cytotoxic Cells with Ly Antisera 
Peritoneal lympho-  Pretreatment  Remaining Meth 4  CMC  Reduction of CMC 
cytes  target cells 
cpm  %  % 
Nonimmune  Diluent only  1,811  0 
Immune  Diluent only  515  72 
Immune  Anti-Ly-  1.1  529  71  Standard 
Immune  Anti-Ly-l.2  1,268  30  58 
Immune  Anti-Ly-2.2  1,501  17  76 
Immune  Anti-Ly-3.2  1,192  34  52 
PRETREATMENT 
Oiluem only 
Anii-Ly-1  1 
Anti-Ly-12 
{unabsorbed) 
Antl-Ly-l.2 
(abs with B6) 
Anti-Ly-1 2 
(abs  with  B6/ty-1  1) 
CMC (%)  PRETREATMENT  CMC (~) 
20  40  60  20  40 
i 
80 
(3  [Nuent onty 
Anti-Ly 1 1 
Anb-Ly-3 2 
[unabsorbed) 
Anli-Ly 32 
labs  with B6} 
Anti-Ly-32 
(abs with B6/Ly 21 Ly-31) 
FIG.  2.  Ly  antisera,  (a)  unabsorbed,  (b)  absorbed  (abs.)  with  B6  thymocytes,  or  (c) 
abso  )ed with thymocytes from Ly congenic B6 mice were used to pretreat effector cells. 
(2a) Ly-l.2 antiserum, which virtually abolished cytotoxicity when used unabsorbed, lost 
its inhibitory effect when absorbed with B6 thymocytes, but not with B6/Ly-1.1 thymocytes. 
(2 b ) The inhibitory activity of Ly-3.2 antiserum was removed with B6 thymocytes, but not 
with B6/Ly-2.1,  3.1 thymocytes.  Anti-Ly-l.1 serum was used as an additional specificity 
control. 
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TABLE  III 
Failure to Reconstitute Syngeneic Cytotoxicity  by Mixing Effector Cell Populations 
Pretreated with Either Anti-Ly-1 2  Serum or Anti-Ly-3.2 Serum 
Peritoneal  lymphc-  Pretreatment  Remaining Meth 4  CMC  Reduction of  CMC 
cytes  target  cells 
cprn  %  % 
Nonimmune  Diluent only  1,710  0 
Immune  Diluent only  1,121  34 
Immune  Anti-Ly-1.1  857  50  Standard 
Immune  Anti-Ly-l.2  1,790  0  100 
Immune  Anti-Ly-3.2  1,845  0  100 
Immune+  Anti-Ly-l.2 t 
Immune  Anti-Ly-3.2 
1,803  0  10O 
Immune lymphocytes were pretreated with one of the following: (a) diluent only, (b) anti-Ly-1.1 serum (standard), (c) anti-Ly-l.2 
serum,  or (d) anti-Ly-3.2 serum.  Subsequently, 3  x  l0  s lymphocytes treated with anti-Ly-l.2 and C  were mixed with 3  x  l0 s 
lymphocytes treated with anti-Ly-3.2 and C. The reconstituted cell population lacked cytotoxic activity. 
Similarly, anti-Ly-3.2 was no longer effective in reducing lymphocyte cytotoxic- 
ity after absorption with B6 thymocytes (phenotype Ly-3.2), but retained that 
activity after absorption with B6/Ly-2.1,3.1. 
These results suggested that Ly-1, as well as Ly-2/3 were represented on the 
surface of syngeneic cytotoxic cells. To determine whether some cytotoxic cells 
express Ly-1, and others Ly-2/3, or whether the phenotype of all cytotoxic cells 
was  Ly-l,2,3,  experiments of the type shown in  Table  III  were undertaken. 
Effector cells were pretreated with either anti-Ly-l.2 or anti-Ly-3.2 serum, and 
then mixed in equal proportions to obtain a  mixture that contained Ly-1 cells 
and Ly-2/3 cells, but not Ly-l,2,3 cells.  This mixture (on line 6 in Table III) 
showed no cytotoxicity, demonstrating that lymphocyte cytotoxicity for synge- 
neic tumor cells is mediated by cells that carried both Ly-1 and Ly-2/3 on their 
surface.  The results  do not rule out the possibility that Ly-l,2,3  T  cells are 
required to  cooperate with  other T  cells in  syngeneic cell killing or that an 
increase in  the proportion  of suppressor  cells  might  account for the  lack of 
cytotoxicity in the experiment with mixed effector cell populations. 
Summary 
Our present and previous findings may be summarized as follows: The pheno- 
type of C57BL/6 (B6) cytotoxic cells for allogeneic target cells is Thy-1  +, Ly-l-, 
Ly-2/3 +,  MSLA  +,  and Ig-.  The phenotype of B6  cytotoxic cells for syngeneic 
tumor cells is Thy-1  +, Ly-1  +, Ly-2/3  +, MSLA  +, and Ig-. Thus, differences in Ly 
phenotype appear to be exhibited not only by cytotoxic T  cells as opposed to 
helper T cells, but also within subcategories of cytotoxic T cells. 
subcategories of cytotoxic T cells. 
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